Literature DB >> 29365205

The siren song of bevacizumab: swan song or clarion call?

David Schiff1, Patrick Y Wen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29365205      PMCID： PMC5777485          DOI： 10.1093/neuonc/nox244

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  15 in total

1.  Methods for adjusting for bias due to crossover in oncology trials.

Authors:  K Jack Ishak; Irina Proskorovsky; Beata Korytowsky; Rickard Sandin; Sandrine Faivre; Juan Valle
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

2.  Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

Authors:  Thomas Sandmann; Richard Bourgon; Josep Garcia; Congfen Li; Timothy Cloughesy; Olivier L Chinot; Wolfgang Wick; Ryo Nishikawa; Warren Mason; Roger Henriksson; Frank Saran; Albert Lai; Nicola Moore; Samir Kharbanda; Franklin Peale; Priti Hegde; Lauren E Abrey; Heidi S Phillips; Carlos Bais
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

3.  Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.

Authors:  Philipp Kickingereder; Michael Götz; John Muschelli; Antje Wick; Ulf Neuberger; Russell T Shinohara; Martin Sill; Martha Nowosielski; Heinz-Peter Schlemmer; Alexander Radbruch; Wolfgang Wick; Martin Bendszus; Klaus H Maier-Hein; David Bonekamp
Journal:  Clin Cancer Res       Date:  2016-10-10       Impact factor: 12.531

4.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Authors:  Kathleen M Schmainda; Zheng Zhang; Melissa Prah; Bradley S Snyder; Mark R Gilbert; A Gregory Sorensen; Daniel P Barboriak; Jerrold L Boxerman
Journal:  Neuro Oncol       Date:  2015-02-02       Impact factor: 12.300

7.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

8.  Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.

Authors:  Lale Erdem-Eraslan; Martin J van den Bent; Youri Hoogstrate; Hina Naz-Khan; Andrew Stubbs; Peter van der Spek; René Böttcher; Ya Gao; Maurice de Wit; Walter Taal; Hendrika M Oosterkamp; Annemiek Walenkamp; Laurens V Beerepoot; Monique C J Hanse; Jan Buter; Aafke H Honkoop; Bronno van der Holt; René M Vernhout; Peter A E Sillevis Smitt; Johan M Kros; Pim J French
Journal:  Cancer Res       Date:  2016-01-13       Impact factor: 12.701

9.  Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.

Authors:  Olivier L Chinot; Ryo Nishikawa; Warren Mason; Roger Henriksson; Frank Saran; Timothy Cloughesy; Josep Garcia; Cedric Revil; Lauren Abrey; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2016-03-22       Impact factor: 12.300

10.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
View more
  3 in total

1.  Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway.

Authors:  Jinhua Long; Zuquan Hu; Hui Xue; Yun Wang; Jin Chen; Fuzhou Tang; Jing Zhou; Lina Liu; Wei Qiu; Shichao Zhang; Yan Ouyang; Yuannong Ye; Guoqiang Xu; Long Li; Zhu Zeng
Journal:  Cancer Sci       Date:  2019-06-28       Impact factor: 6.716

Review 2.  Impact of General Factors on Glioma Immunotherapy.

Authors:  Qilin Huang; Dongmei Wang; Guojie Yao; Hongxiang Wang
Journal:  J Clin Neurol       Date:  2022-01       Impact factor: 3.077

3.  Exosomal miR-301a-3p from esophageal squamous cell carcinoma cells promotes angiogenesis by inducing M2 polarization of macrophages via the PTEN/PI3K/AKT signaling pathway.

Authors:  Yuwei Shou; Xiaoqian Wang; Chao Chen; Yinghao Liang; Chenbo Yang; Qiankun Xiao; Hui Li; Shuaiyuan Wang; Jiao Shu; Xiangyu Tian; Kuisheng Chen
Journal:  Cancer Cell Int       Date:  2022-04-18       Impact factor: 5.722
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.